Opportunity Information: Apply for PA 09 159
Apply for PA 09 159
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Developmental Research in Cancer Prognosis and Prediction (R33)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Apr 14, 2009 and posted on Apr 14, 2009.
- Applicants must submit their applications by May 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) County governments Native American tribal governments (Federally recognized) City or township governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Developmental Research in Cancer Prognosis and Prediction (R33) opportunity (Funding Opportunity Number PA 09 159) is a National Cancer Institute (NCI), National Institutes of Health (NIH) funding announcement designed to move promising cancer biomarkers and related prediction tools closer to real clinical use. The main focus is on studies that evaluate the usefulness of new or improved strategies for determining a cancer patient's prognosis or predicting how a patient will respond to a specific therapy. In practical terms, this program is meant to take early, correlative research findings (for example, an observed association between a molecular marker and treatment response) and push them forward into more mature, better-characterized assays or test systems that can be used in clinical trials or other confirmatory clinical research settings. The end goal is to generate tools that can genuinely improve clinical decision making, such as helping clinicians choose the most appropriate therapy, avoid ineffective treatments, or better estimate outcomes for individual patients.
The award uses the NIH Exploratory/Developmental Phase II Research Grant (R33) mechanism, which generally supports the later stages of exploratory development where there is a need to refine, pilot, and demonstrate feasibility and utility prior to broader validation efforts. The announcement notes that it runs in parallel with a separate but scientifically identical funding opportunity that uses the R21 mechanism (PA 09 158). In other words, applicants pursuing similar scientific aims could consider whether their project fits better as an earlier-stage exploratory effort under an R21 or a more advanced developmental effort under an R33, depending on how ready the biomarker or test system is for piloting and preparation for confirmatory clinical research.
Funding levels and the number of awards are not fixed in advance because the NIH expects proposed projects to vary widely in scope, approach, and resource needs. As a result, the size and duration of each award can differ substantially from one application to another. The total funds committed and the number of funded projects depend on how many applications are submitted, their overall scientific merit and relevance, and the requested budgets and project periods.
Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Eligible applicants listed include small businesses; for-profit organizations (other than small businesses); nonprofit organizations with or without 501(c)(3) status; public and private institutions of higher education; and a wide range of government entities such as state governments, counties, cities or townships, and special district governments. The eligibility language also explicitly includes organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, federally recognized tribal governments, other tribal entities, regional organizations, and U.S. territories or possessions. Foreign (non-U.S.) entities are also indicated as eligible under the additional eligibility information.
Administratively, the opportunity was posted and created on April 14, 2009, with an original and final closing date of May 7, 2012, and it was archived on June 7, 2012. The program is categorized as a discretionary grant opportunity and is associated with CFDA numbers 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research). There is no cost sharing or matching requirement stated for applicants. For complete details, the full announcement was hosted by NIH at the link provided in the source text (http://grants.nih.gov/grants/guide/pa-files/PA-09-159.html), and general technical support for accessing the announcement was routed through the NIH Office of Extramural Research (OER) webmaster contact.
Frequently Asked Questions (FAQs)
What is the Developmental Research in Cancer Prognosis and Prediction (R33) opportunity?
This is a National Cancer Institute (NCI), National Institutes of Health (NIH) funding announcement called "Developmental Research in Cancer Prognosis and Prediction (R33)" under Funding Opportunity Number (FON) PA 09 159.
What is the main purpose of this funding opportunity?
The program is designed to move promising cancer biomarkers and related prediction tools closer to real clinical use by supporting studies that evaluate strategies for determining a cancer patient's prognosis or predicting how a patient will respond to a specific therapy.
What types of studies does this announcement emphasize?
It emphasizes studies that evaluate the usefulness of new or improved strategies for cancer prognosis or therapy response prediction, especially those that help translate early correlative findings into more mature, well-characterized assays or test systems suitable for clinical trials or other confirmatory clinical research settings.
What does "prognosis" mean in the context of this opportunity?
In this context, prognosis refers to estimating outcomes for individual cancer patients, such as likely disease course or survival-related expectations, using biomarkers or related tools intended to improve clinical decision making.
What does "prediction" mean in the context of this opportunity?
Here, prediction refers to forecasting how a patient will respond to a specific therapy, using biomarkers or related prediction tools to help clinicians choose appropriate treatment and avoid ineffective options.
What kinds of biomarker-related work is this program trying to advance?
The program is intended to take early, correlative research findings (for example, an observed association between a molecular marker and treatment response) and move them toward refined, better-characterized assays or test systems that can be used in clinical trials or other confirmatory clinical research.
What is the intended end goal of the funded research?
The end goal is to generate tools that can genuinely improve clinical decision making, such as helping clinicians select the most appropriate therapy, avoid ineffective treatments, or better estimate outcomes for individual patients.
What grant mechanism does this opportunity use?
This opportunity uses the NIH Exploratory/Developmental Phase II Research Grant (R33) mechanism.
What does the R33 mechanism generally support?
It generally supports later stages of exploratory development where there is a need to refine, pilot, and demonstrate feasibility and utility prior to broader validation efforts.
Is there a related NIH opportunity connected to this announcement?
Yes. This announcement runs in parallel with a separate but scientifically identical funding opportunity that uses the R21 mechanism (PA 09 158).
How should an applicant think about choosing between R21 and R33 for similar scientific aims?
Based on the announcement description, applicants pursuing similar scientific aims could consider R21 for an earlier-stage exploratory effort, while R33 may be a better fit for a more advanced developmental effort where the biomarker or test system is ready for piloting and preparation for confirmatory clinical research.
Are the funding levels and number of awards fixed?
No. Funding levels and the number of awards are not fixed in advance because projects are expected to vary widely in scope, approach, and resource needs.
What factors influence the total funds committed and the number of funded projects?
The total funds committed and the number of funded projects depend on how many applications are submitted, their overall scientific merit and relevance, and the requested budgets and project periods.
Can the size and duration of awards vary from one award to another?
Yes. The announcement indicates that the size and duration of each award can differ substantially across applications.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S. and non-U.S. organizations, including small businesses; for-profit organizations (other than small businesses); nonprofit organizations with or without 501(c)(3) status; public and private institutions of higher education; and many government entities.
What types of government entities are included as eligible applicants?
Eligible government entities listed include state governments, counties, cities or townships, and special district governments.
Are minority-serving institutions explicitly included?
Yes. The eligibility language explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and other related entities listed in the announcement summary.
Are tribal organizations eligible?
Yes. Federally recognized tribal governments and other tribal entities are explicitly included as eligible applicants.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are explicitly indicated as eligible under the listed applicant categories.
Are foreign (non-U.S.) entities eligible to apply?
Yes. Foreign (non-U.S.) entities are indicated as eligible under the additional eligibility information described in the opportunity summary.
Is cost sharing or matching required?
No. The opportunity states that there is no cost sharing or matching requirement.
When was this funding opportunity posted and created?
It was posted and created on April 14, 2009.
What were the closing dates for this opportunity?
The announcement lists an original closing date and a final closing date of May 7, 2012.
When was the opportunity archived?
The opportunity was archived on June 7, 2012.
How is this opportunity categorized?
It is categorized as a discretionary grant opportunity.
What CFDA numbers are associated with this program?
The opportunity is associated with CFDA 93.394 (Cancer Detection and Diagnosis Research) and CFDA 93.395 (Cancer Treatment Research).
Where can applicants find the full NIH announcement?
The full announcement was hosted by NIH at: http://grants.nih.gov/grants/guide/pa-files/PA-09-159.html
Where is technical support directed for accessing the announcement?
General technical support for accessing the announcement was routed through the NIH Office of Extramural Research (OER) webmaster contact, as noted in the opportunity summary.
Browse more opportunities from the same category: Education Health
Next opportunity: NCMHD Exploratory Centers of Excellence (P20)
Previous opportunity: Developmental Research in Cancer Prognosis and Prediction (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 159
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 159) also looked into and applied for these:
| Funding Opportunity |
|---|
| Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities (R21) Apply for PAR 09 160 Funding Number: PAR 09 160 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Basic Cancer Research in Cancer Health Disparities (U01) Apply for PAR 09 161 Funding Number: PAR 09 161 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Developmental Projects in Complementary Approaches to Cancer Care and Treatment (R21) Apply for PA 09 167 Funding Number: PA 09 167 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Developmental Projects in Complementary Approaches to Cancer Care and Treatment (R03) Apply for PA 09 168 Funding Number: PA 09 168 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Minority Based Community Clinical Oncology Program (U10) Apply for RFA CA 09 023 Funding Number: RFA CA 09 023 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Renewal of Centers of Biomedical Research Excellence (COBRE)P20 Apply for PAR 09 180 Funding Number: PAR 09 180 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Centers of Biomedical Research Excellence (COBRE) Phase III Transitional Centers P30 Apply for RFA RR 09 005 Funding Number: RFA RR 09 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Community Clinical Oncology Program (U10) Apply for RFA CA 09 022 Funding Number: RFA CA 09 022 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Technologies and Software to Support Integrative Cancer Biology Research (SBIR) R43/R44 Apply for PA 09 188 Funding Number: PA 09 188 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Technology Development for the Detection and Evaluation of Chemical and Biological Carcinogens (SBIR) R43/R44 Apply for PA 09 187 Funding Number: PA 09 187 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Technology for the Detection and Characterization of Low Abundance Proteins, Peptides, or micro RNAs (SBIR) R43/R44 Apply for PA 09 189 Funding Number: PA 09 189 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Integrating Translational Neuroscience and Adolescent Drug Abuse Treatment (R21) Apply for RFA DA 10 003 Funding Number: RFA DA 10 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| International Research Collaborations on HIV/AIDS and Drug Use (R01) Apply for RFA DA 10 008 Funding Number: RFA DA 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Centers of Cancer Nanotechnology Excellence (CCNEs)(U54) Apply for RFA CA 09 012 Funding Number: RFA CA 09 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $3,200,000 |
| Cancer Nanotechnology Platform Partnerships (U01) Apply for RFA CA 09 013 Funding Number: RFA CA 09 013 Agency: National Institutes of Health Category: Education Health Funding Amount: $400,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R01) Apply for PA 09 197 Funding Number: PA 09 197 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R21) Apply for PA 09 198 Funding Number: PA 09 198 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Identifying Non coding RNA Targets for Cancer Early Detection and Prevention (R21) Apply for PA 09 200 Funding Number: PA 09 200 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Identifying Non coding RNA Targets for Cancer Early Detection and Prevention (R01) Apply for PA 09 199 Funding Number: PA 09 199 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The National Drug Abuse Treatment Clinical Trials Network (U10) Apply for RFA DA 10 009 Funding Number: RFA DA 10 009 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 159", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.